9/11 Responder and Survivor Health Funding Correction Act of 2025
Summary
HR1410 is an early-stage bill modifying the World Trade Center Health Program's funding formula and expanding mental health provider eligibility. It does not appropriate funds, has only been referred to committee, and has no direct near-term market impact on publicly traded healthcare companies.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR1410 is pre-procedural with no appropriations and no near-term market impact
- 2.No publicly traded company's revenue or competitive position is directly affected
- 3.Recent 30-day rallies in HUM (+46.46%) and CNC (+69.75%) are unrelated to this bill
Market Implications
No actionable market implications from this bill. The WTCHP is a small, closed federal program with no derivative impact on large-cap managed care stocks. Recent price action in HUM and CNC reflects separate sector dynamics (likely related to Medicare Advantage rate announcements or broader healthcare policy), not HR1410. Investors should ignore this bill for portfolio decisions.
Full Analysis
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Protecting Health Care and Lowering Costs Act of 2025
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
DELL FEDERAL SYSTEMS L.P: $602M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
Consolidated Appropriations Act, 2026
Veterans SPORT Act
American Innovation and R&D Competitiveness Act of 2025
Association Health Plans Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.